Fosamax, a popular treatment for osteoporosis, is associated with severe bone diseases, femur fractures, osteonecrosis of the jaw (ONJ), heart rhythm problems, and more. If you were injured, you are not alone — Merck & Co. is facing hundreds of lawsuits in federal court.
Fosamax Class Action Lawsuit Information
Fosamax (alendronate) is an anti-osteoporosis drug that has been heavily marketed to older men and women since the 1990s. In August 2004, the U.S. Food and Drug Administration (FDA) confirmed that Fosamax and other drugs in the bisphosphonate family might cause Osteonecrosis of the Jaw, or “Dead Jaw Syndrome.” Studies have also linked Fosamax and femur fractures.
In recent years, hundreds of people who were injured by Fosamax have filed lawsuits. In 2008, plaintiffs asked federal judges to certify the litigation into a class action lawsuit, but these claims were denied. Instead, over 900 individual lawsuits were centralized in a Multi-District Litigation (MDL No. 1789) in the U.S. District Court for the Southern District of New York.
In May 2014, a New Jersey federal judge tossed several Fosamax lawsuits filed by people who were injured by generic versions of the drug. The judge pointed to two recent Supreme Court decisions that generic drug manufacturers cannot be sued for defects caused by brand-name drugs.
What is the problem?
- Femur fractures
- Esophagus irritation, inflammation, or ulcers
- Esophageal cancer
- Low blood calcium levels (hypocalcemia)
- Severe muscle spasms, twitches, cramps, numbness, tingling
- Osteonecrosis in the jaw (bone death and decay) or “Dead Jaw Syndrome”
- Bone, muscle and joint pain
- Atrial fibrillation (irregular heartbeat)
- And more